The COVID-19 pandemic has acted as a catalyst for life sciences organizations to continue shifting away from volume to value-based care (VBC) solutions to help decrease overall costs while also improving the quality of care to specific populations. While clinical and market research findings are important to demonstrate your product is safe and effective, there is also a growing need to include additional economical evidence to verify the additional cost savings that providers, payers and patients will receive from your new product or device.
Join Baker Tilly for an informative discussion regarding what factors life sciences companies should consider when conducting pre-launch planning and formulating go-to-market strategies for their products in today’s unique environment. Our team of Value Architects™ will discuss:
Who should attend?
C-Suite, VPs, senior executives, directors, and commercial, marketing, and sales professionals of clinical development, private equity, and emerging commercial pharmaceutical and life sciences organizations
Key learning objectives
There are no prerequisites for this event and advance preparation is not required. There is no cost to attend this event.
CPE credit: One (1) hour total credit
Field of study: Management Advisory Services
CPE host: Morgan Tomko
A certificate of completion will be e-mailed to you four to six weeks after the event.
For more information regarding administrative policies such as complaint and refund, please contact our offices at +1 (608) 240 2522.
Baker Tilly US, LLP is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: nasbaregistry.org.